QuidelOrtho (QDEL)
Runs hospital lab instruments and point-of-care rapid tests under one roof.
Something off on this page? Send us feedback.
Pairs a central-lab reagents-and-instruments franchise built around VITROS chemistry and immunoassay analyzers with a point-of-care rapid-test line built around Sofia and QuickVue, plus smaller immunohematology and molecular-testing units, selling mostly on recurring reagents and service contracts.
Two diagnostics franchises sit under one roof: a central-lab business selling VITROS chemistry and immunoassay analyzers with the reagents and service contracts that keep them running, and a point-of-care line built around the Sofia analyzer and QuickVue rapid tests for clinics and home use. A transfusion-medicine unit and a smaller molecular line round out the portfolio.
The lab business is the largest and steadiest, anchored in recurring reagents; point-of-care swings with flu and respiratory demand. Hospitals, reference labs, and blood banks across North America, Europe, and China make up most sales.
Respiratory testing is a shrinking share of revenue after the pandemic surge. US donor-screening is winding down, one molecular platform is being retired for an acquired successor, and a blood-products joint arrangement ended in early 2026. Leadership turned over after a 2024 guidance shortfall. Predecessor Quidel traces to 1979.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 7, 2026 | UBS | Target | Target: $17 | Target: $12 |
| May 7, 2026 | Jefferies | Downgrade | Target: — | Target: $12.50 |
| Apr 10, 2026 | UBS | Reiterate | Rating: —Target: $30 | Target: $17 |
| Feb 12, 2026 | UBS | Target | Target: $35 | Target: $30 |
| Jan 21, 2026 | UBS | Reiterate | Rating: —Target: $50 | Target: $35 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 28, 2026Cash & short-term investments $123.4M · Total debt $3.08B · Total assets $5.72B · Shareholders' equity $1.77B
- Revenue
- $630.9M
- Operating income
- −$21.8M
- Net income
- −$92.9M
No dividends on record.
| Institutions | 123.18% | 84.00M shares | |
|---|---|---|---|
| 256 holders · as of Jun 30, 2026 | |||
| Insiders | 0.86% | 584.8K shares | |
| 18 holders · as of Sep 17, 2026 | |||
| Adds to | 124.04% | ||
68.19M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 124.04%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 16.43% | 11.20M | as of Jun 30, 2026 |
FMR LLCInstitution | 10.80% | 7.36M | as of Jun 30, 2026 |
Newtyn Management, LLCInstitution | 9.72% | 6.63M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 6.06% | 4.14M | as of Jun 30, 2026 |
Neuberger Berman Group LLCInstitution | 5.18% | 3.53M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 13, 2026 | Brian J. Blaser | officer: President and CEO | +10,540 | $23.59 |
| Feb 13, 2026 | Joseph M. Busky | officer: Chief Financial Officer | +3,370 | $23.66 |
| Feb 13, 2026 | Matthew Strobeck | director | +10,000 | $23.96 |
| Dec 10, 2025 | Ann D. Rhoads | director | +750 | $28.28 |
| Nov 26, 2025 | Joseph D. Jr. Wilkins | director | +370 | $27.96 |
- Abbott
Broadest head-to-head across labs, point-of-care, cardiac, and molecular.
- Danaher
Beckman Coulter and Cepheid combine for a two-front lab and molecular rival.
- Bio-Rad Laboratories
IH-1000 is the direct gel-card rival to ORTHO VISION in immunohematology.
- Grifols (ADR)
Direct transfusion-medicine rival since the 2026 joint-business exit.
- BD
BD Veritor contests rapid antigen point-of-care testing head-to-head.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| QuidelOrtho | $10.67 | −2.51% | $746.0M | — | 12.7 | 0.3 | +2.8% |
| Abbott | $104.26 | +0.51% | $179.49B | 33.4 | 18.0 | 3.9 | +13.0% |
| Danaher | $221.17 | +0.04% | $155.44B | 39.3 | 25.0 | 6.2 | +5.5% |
| Bio-Rad Laboratories | $377.47 | −0.55% | $10.22B | 46.0 | 36.6 | 3.9 | −0.1% |
| Grifols (ADR) | $7.30 | −1.95% | $6.29B | 9.7 | — | 0.7 | −1.8% |
| BD | $183.24 | +0.13% | $50.42B | 55.1 | 13.8 | 2.4 | −9.6% |
| Median | 39.3 | 21.5 | 3.9 | −0.1% |